Inhibition of CDK6 by shRNA or pharmacological inhibitor (e.g., PD-0332991) decreases leukemic cell growth and promotes myeloid cell differentiation in cell lines and primary human AML cells harboring different KMT2A translocations. This evidence concerns the gene KMT2A and acute myeloid leukemia.